Your browser is no longer supported. Please, upgrade your browser.
EXAS Exact Sciences Corporation weekly Stock Chart
Exact Sciences Corporation
Index- P/E- EPS (ttm)-1.04 Insider Own0.80% Shs Outstand149.73M Perf Week-5.27%
Market Cap10.67B Forward P/E- EPS next Y-1.37 Insider Trans-13.19% Shs Float148.61M Perf Month-10.22%
Income-154.40M PEG- EPS next Q-0.53 Inst Own91.60% Short Float8.86% Perf Quarter-16.68%
Sales1.13B P/S9.43 EPS this Y55.40% Inst Trans1.58% Short Ratio9.37 Perf Half Y55.77%
Book/sh16.77 P/B4.38 EPS next Y39.10% ROA-4.30% Target Price116.50 Perf Year-29.30%
Cash/sh8.42 P/C8.73 EPS next 5Y- ROE-7.60% 52W Range35.25 - 113.10 Perf YTD-20.51%
Dividend- P/FCF- EPS past 5Y12.50% ROI-1.90% 52W High-34.63% Beta1.62
Dividend %- Quick Ratio6.40 Sales past 5Y244.80% Gross Margin75.10% 52W Low109.72% ATR3.16
Employees4110 Current Ratio6.80 Sales Q/Q34.50% Oper. Margin-24.20% RSI (14)38.83 Volatility3.82% 4.34%
OptionableYes Debt/Eq0.62 EPS Q/Q-93.40% Profit Margin-13.60% Rel Volume0.21 Prev Close73.51
ShortableYes LT Debt/Eq0.62 EarningsJul 30 AMC Payout- Avg Volume1.41M Price73.93
Recom1.30 SMA20-2.47% SMA50-13.19% SMA200-10.84% Volume16,789 Change0.57%
Apr-02-20Initiated Evercore ISI Outperform $70
Jan-10-20Resumed BTIG Research Buy $127
Jan-07-20Initiated Citigroup Buy $120
Dec-13-19Initiated Dougherty & Company Buy $120
Nov-15-19Initiated Stifel Buy
Oct-17-19Reiterated BofA/Merrill Buy $130 → $135
Oct-01-19Resumed Craig Hallum Buy $127
Sep-26-19Initiated Oppenheimer Outperform $130
Feb-26-19Upgrade Goldman Neutral → Buy $85 → $120
Oct-09-18Initiated UBS Buy
Sep-05-18Resumed The Benchmark Company Hold
Aug-13-18Reiterated Canaccord Genuity Buy $62 → $65
Apr-03-18Upgrade BTIG Research Neutral → Buy
Jan-29-18Initiated Goldman Neutral $51
Jan-08-18Reiterated The Benchmark Company Buy $60 → $65
Nov-13-17Downgrade Robert W. Baird Outperform → Neutral $56
Nov-01-17Downgrade BTIG Research Buy → Neutral
Oct-31-17Reiterated The Benchmark Company Buy $50 → $60
Oct-03-17Reiterated Canaccord Genuity Buy $45 → $60
Sep-21-17Reiterated Leerink Partners Outperform $45 → $50
Sep-21-20 04:27PM  
Sep-17-20 06:00AM  
Sep-07-20 12:52PM  
Sep-01-20 04:05PM  
Aug-29-20 11:31AM  
Aug-01-20 04:03AM  
Jul-31-20 12:13PM  
Jul-30-20 06:30PM  
Jul-29-20 08:40AM  
Jul-23-20 12:32PM  
Jul-17-20 08:00AM  
Jul-12-20 12:00PM  
Jul-08-20 07:45AM  
Jun-16-20 03:09PM  
Jun-05-20 11:31AM  
Jun-03-20 09:49AM  
May-29-20 08:00AM  
May-26-20 06:00AM  
May-17-20 06:46AM  
May-12-20 03:10PM  
May-11-20 10:19AM  
May-07-20 11:30AM  
May-06-20 08:05PM  
May-05-20 10:30AM  
May-04-20 06:00AM  
May-03-20 07:36AM  
Apr-30-20 10:49AM  
Apr-29-20 12:34PM  
Apr-22-20 05:20AM  
Apr-08-20 05:51PM  
Apr-02-20 09:00AM  
Mar-26-20 05:45PM  
Mar-24-20 09:44AM  
Mar-21-20 09:22AM  
Mar-19-20 06:00AM  
Mar-17-20 05:45PM  
Mar-12-20 11:30AM  
Mar-04-20 07:37AM  
Feb-27-20 08:42AM  
Feb-25-20 08:28AM  
Feb-24-20 10:39PM  
Feb-19-20 05:44AM  
Feb-17-20 05:24AM  
Feb-12-20 03:52PM  
Feb-11-20 06:15PM  
Feb-04-20 06:41PM  
Feb-03-20 05:45PM  
Jan-27-20 05:50PM  
Jan-24-20 11:24AM  
Jan-23-20 01:30PM  
Jan-22-20 07:30AM  
Jan-21-20 06:31AM  
Jan-20-20 09:13AM  
Jan-17-20 09:15AM  
Jan-16-20 02:53PM  
Jan-15-20 09:36AM  
Jan-14-20 01:44PM  
Jan-13-20 01:51PM  
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; and Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer. The company's pipeline products focuses on the research and development of enhancing Cologuard's performance characteristics, and blood or other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; Biocartis N.V.; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Conroy Kevin TPresident and CEOSep 01Sale75.0319,9271,495,123948,339Sep 02 04:32 PM
Hoof TorstenGeneral Manager, InternationalAug 19Option Exercise43.401,51665,7949,981Aug 21 04:31 PM
Hoof TorstenGeneral Manager, InternationalAug 19Sale84.907,964676,1442,017Aug 21 04:31 PM
Hoof TorstenGeneral Manager, InternationalAug 17Option Exercise0.002,55108,465Aug 19 04:15 PM
Conroy Kevin TPresident and CEOAug 03Sale93.8025,1982,363,560968,266Aug 04 05:18 PM
Carey Thomas D.DirectorJul 31Option Exercise9.2415,620144,32952,492Aug 04 05:21 PM
Zanotti Katherine SDirectorJul 31Option Exercise8.5221,029179,16762,936Aug 04 04:54 PM
LEVANGIE DANIEL JDirectorJul 31Option Exercise9.309,86591,69924,881Aug 04 04:58 PM
Elliott Jeffrey ThomasChief Financial OfficerJul 31Option Exercise21.686,638143,91275,861Aug 04 05:02 PM
Elliott Jeffrey ThomasChief Financial OfficerJul 31Sale93.8337,5003,518,77138,361Aug 04 05:02 PM
LEVANGIE DANIEL JDirectorJul 31Sale94.009,865927,31015,016Aug 04 04:58 PM
Zanotti Katherine SDirectorJul 31Sale94.0021,0291,976,72641,907Aug 04 04:54 PM
Doyle James EdwardDirectorJul 31Sale94.002,539238,66632,459Aug 04 04:45 PM
Carey Thomas D.DirectorJul 31Sale94.0030,6202,878,28021,872Aug 04 05:21 PM
Elliott Jeffrey ThomasChief Financial OfficerJul 29Sale95.588,746835,94369,223Jul 30 08:18 PM
Elliott Jeffrey ThomasChief Financial OfficerJul 28Option Exercise94.8118,7501,777,68877,969Jul 30 08:18 PM
Zanotti Katherine SDirectorJul 28Sale96.131,164111,89541,907Jul 30 06:49 PM
Stenhouse MarkPresident, CologuardApr 03Sale56.6911,948677,33229,571Apr 06 04:41 PM
Stenhouse MarkPresident, CologuardApr 02Option Exercise0.0025,000041,519Apr 06 04:41 PM
Doyle James EdwardDirectorFeb 28Sale77.542,000155,08032,440Mar 03 07:20 PM
Conroy Kevin TPresident and CEOFeb 28Sale80.179,750781,658992,963Mar 02 07:13 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 28Sale80.172,383191,04558,578Mar 02 07:15 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 27Option Exercise0.005,025061,141Mar 02 07:15 PM
Conroy Kevin TPresident and CEOFeb 27Option Exercise0.0020,57501,002,713Mar 02 07:13 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 27Sale80.271,627130,59956,116Feb 28 04:37 PM
Stenhouse MarkPresident, CologuardFeb 27Sale80.271,05184,36416,519Feb 28 04:39 PM
Conroy Kevin TPresident and CEOFeb 27Sale80.2713,8751,113,746982,138Feb 28 04:36 PM
Conroy Kevin TPresident and CEOFeb 26Option Exercise0.0029,3370996,013Feb 28 04:36 PM
Stenhouse MarkPresident, CologuardFeb 26Option Exercise0.003,262017,570Feb 28 04:39 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 26Option Exercise0.003,436057,743Feb 28 04:37 PM
Conroy Kevin TPresident and CEOFeb 25Sale85.1118,1151,541,768966,676Feb 26 05:11 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 25Sale85.114,910417,89054,307Feb 26 05:13 PM
Elliott Jeffrey ThomasChief Financial OfficerFeb 24Option Exercise0.009,300059,217Feb 26 05:13 PM
Conroy Kevin TPresident and CEOFeb 24Option Exercise0.0034,3250984,791Feb 26 05:11 PM
Cole G BradleyGeneral Manager - DiagnosticsFeb 19Option Exercise35.7717,356620,77637,550Feb 21 04:58 PM
Cole G BradleyGeneral Manager - DiagnosticsFeb 19Sale100.0027,3562,735,60010,194Feb 21 04:58 PM
ORVILLE JACOB AGeneral Manager, New VenturesFeb 19Sale100.681,153116,0842,495Feb 20 05:55 PM
ORVILLE JACOB AGeneral Manager, New VenturesFeb 18Option Exercise0.003,64803,648Feb 20 05:55 PM
Hoof TorstenGeneral Manager, InternationalFeb 15Option Exercise0.002,09105,914Mar 27 04:15 PM
Cole G BradleyGeneral Manager - DiagnosticsJan 16Sale90.3010,000903,0008,653Jan 17 04:50 PM
Conroy Kevin TPresident and CEODec 16Option Exercise17.4811,440199,992950,466Dec 18 05:19 PM
Cole G BradleyGeneral Manager - DiagnosticsNov 21Sale80.3828,0162,251,92630,987Nov 25 05:18 PM